Publication
Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses
Journal Paper/Review - Oct 26, 2021
Schmiedeberg Kristin, Vuilleumier Nicolas, Pagano Sabrina, Albrich Werner, Ludewig Burkhard, von Kempis Johannes, Rubbert-Roth Andrea
Units
Rheumatologie, Division of Infectious Diseases & Hospital Epidemiology, Medizinisches Forschungszentrum, Institute of Immunobiology
PubMed
Doi
Citation
Schmiedeberg K, Vuilleumier N, Pagano S, Albrich W, Ludewig B, von Kempis J, Rubbert-Roth A. Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses. Lancet Rheumatol 2021; 4:e11-e13.
Type
Journal Paper/Review (English)
Journal
Lancet Rheumatol 2021; 4
Publication Date
Oct 26, 2021
Issn Electronic
2665-9913
Pages
e11-e13